Seattle could waltz in where Astra failed
Despite Astrazeneca stacking the odds in its favour Imfinzi’s Danube trial, in first-line bladder cancer, reads out negatively.
To challenge Ocrevus, German Merck takes on Aubagio
Six months after evobrutinib’s two pivotal multiple sclerosis studies started enrolment, their comparator cohorts are overhauled.
Multiple sclerosis “win” makes the Principia shorts squirm
Investors betting on the Principia short thesis face up to a clinical trial success that might not be what it seems.
The joker in Exelixis and Bristol’s kidney cancer pack
The first-line Checkmate-9ER study will read out soon, and could show whether two arch rivals can together defeat a common enemy.
Surprise! There’s a tumour in which Keytruda doesn’t work
The Merck & Co drug’s failure in small-cell lung cancer prompts a theory and leaves the way clear for Roche and Astrazeneca.
Corporate and regulatory developments over the Christmas period
On the corporate front Astellas continued to buy, while Qiagen decided that it was not, after all, up for sale.
Esmo 2019 makes for a disappointing read-across to biotech
An analysis of stock market movers during the period of this year’s Esmo congress gives biotech watchers little cause for happiness.
Esmo 2019 preview – Parps on parade
Among small-molecule approaches Europe’s premier oncology conference gives star billing to three Parp inhibitors in ovarian cancer.
World Lung preview – Astra takes on Roche
Astra’s Caspian study is the star of next week’s World Lung conference, which has also given targeted approaches important supporting roles.
